8-K: Terns Pharmaceuticals Announces Second Quarter 2024 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals reported its second quarter 2024 financial results, highlighted by upcoming clinical trial data readouts and a cash runway extending into 2026.

Summary

• Terns Pharmaceuticals announced its financial results for the second quarter of 2024, reporting a net loss of $22.7 million, compared to a $17.9 million loss in the same quarter of 2023.
• The company's cash, cash equivalents, and marketable securities totaled $225.3 million as of June 30, 2024, down from $263.4 million at the end of 2023.
• Terns anticipates that its current cash position will fund operations into 2026.
• Research and development expenses increased to $18.4 million for the quarter, up from $14.2 million in the prior year's quarter.
• General and administrative expenses were $7.2 million, slightly up from $7.0 million in the second quarter of 2023.
• The company expects top-line data from the Phase 1 trial of TERN-601 for obesity in September 2024.
• Interim data from the Phase 1 CARDINAL trial of TERN-701 in chronic myeloid leukemia is expected in December 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's strong cash position, upcoming clinical trial milestones, and progress in its pipeline. However, the increased net loss and personnel changes temper the overall optimism.

Positives

• The company has a strong cash position of $225.3 million, which is expected to fund operations into 2026.
• Terns is progressing multiple clinical programs with key data readouts expected in the near term.
• Preclinical data supports the potential of TERN-501 in combination with GLP-1 agonists for obesity treatment.
• The company is actively exploring new drug candidates, including GIPR modulators for obesity.

Negatives

• The company reported a net loss of $22.7 million for the second quarter of 2024, which is an increase from the $17.9 million loss in the same quarter of 2023.
• Cash reserves decreased from $263.4 million at the end of 2023 to $225.3 million as of June 30, 2024.
• The company is undergoing a transition in key personnel, including the departure of the chief operating officer and a planned transition for the chief financial officer.

Risks

• The company's clinical trials may not produce the desired results.
• There are risks associated with the initiation, cost, timing, progress, results and utility of the company's research and development activities.
• The company's cash runway is dependent on its current operating plan and may be impacted by unforeseen circumstances.
• The company is subject to risks associated with the development of new pharmaceutical products.

Future Outlook

Terns expects to release top-line data from the Phase 1 trial of TERN-601 for obesity in September 2024 and interim data from the Phase 1 CARDINAL trial of TERN-701 in CML in December 2024. The company anticipates its current cash position will fund operations into 2026.

Management Comments

• We are excited about the remainder of 2024 as we progress towards multiple important milestones across our metabolic and oncology franchises, said Amy Burroughs, chief executive officer of Terns.
• Both upcoming readouts represent critical steps forward in our mission to deliver potential best-in-class small-molecule therapies to patients.

Industry Context

The announcement aligns with the broader industry focus on developing novel therapies for obesity and cancer, particularly small-molecule drugs and combination therapies. The company's focus on GLP-1 agonists and BCR-ABL inhibitors places it in competitive but high-potential therapeutic areas.

Comparison to Industry Standards

• Terns' cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• The company's focus on oral GLP-1 agonists for obesity is in line with the industry trend towards more convenient treatment options, with companies like Novo Nordisk and Eli Lilly leading the injectable market.
• The development of an allosteric BCR-ABL inhibitor for CML is a differentiated approach compared to traditional tyrosine kinase inhibitors, with companies like Novartis and Bristol Myers Squibb having established products in this space.
• The combination approach of TERN-501 with GLP-1 agonists is similar to strategies being explored by other companies to enhance weight loss efficacy.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the upcoming clinical trial data and the company's cash runway.
• Employees may be affected by the personnel changes.
• Patients with obesity and CML may benefit from the company's drug development programs.
• Investors will be monitoring the company's financial performance and clinical trial progress.

Next Steps

• Terns plans to release top-line data from the Phase 1 trial of TERN-601 for obesity in September 2024.
• The company expects to share interim data from the Phase 1 CARDINAL trial of TERN-701 in CML in December 2024.
• Terns will host a TERN-701-focused virtual key opinion leader event on August 20, 2024.
• The company is preparing to progress to a 12-week, Phase 2a clinical trial for obesity following supportive data from the Phase 1 trial.
• Terns is continuing discovery efforts for small molecule GIPR modulators for obesity.

Key Dates

Keywords

Terns Pharmaceuticals, TERN-601, TERN-701, TERN-501, GLP-1, BCR-ABL, Obesity, CML, Clinical Trials, Financial Results, Biopharmaceutical, GIPR, THR-beta